Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelets and the hemolytic-uremic syndrome

E C Rossi, F A Carone, F del Greco

    Annals of Clinical and Laboratory Science
    |May 1, 1981
    PubMed
    Summary

    Hemolytic-uremic syndrome (HUS) involves uncontrolled platelet-endothelial interactions, potentially due to prostacyclin defects. Plasma infusion or exchange may offer better remission than anticoagulants for HUS treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?

    Gynecologic oncology·2021
    Same author

    An evolution in sentinel node mapping for cervical cancer.

    BJOG : an international journal of obstetrics and gynaecology·2020
    Same author

    The Medical Bookshelf.

    Postgraduate medicine·2016
    Same author

    Environmental pulmonary edema: an update.

    Reviews on environmental health·1998
    Same author

    Role of the matrix in autosomal dominant polycystic kidney disease.

    Renal failure·1998
    Same author

    Growth factors in metanephric development.

    Renal failure·1998

    Area of Science:

    • Nephrology
    • Hematology
    • Pathophysiology

    Background:

    • Hemolytic-uremic syndrome (HUS) is characterized by microthrombi formation.
    • Uncontrolled platelet-endothelial interactions are implicated in HUS pathogenesis.
    • Defective prostacyclin production, correctable by normal plasma, may be a key mechanism.

    Purpose of the Study:

    • To investigate the role of platelet-endothelial interactions in HUS.
    • To explore prostacyclin production defects as a pathogenic mechanism in HUS.
    • To evaluate the efficacy of plasma infusion/exchange versus hemostatic inhibitors for HUS remission.

    Main Methods:

    • Analysis of clinical studies on HUS.
    • Assessment of prostacyclin production in HUS patients.
    • Review of case reports on plasma therapy and hemostatic inhibitors in HUS.

    Main Results:

    • Clinical studies suggest microthrombi in HUS result from platelet-endothelial interactions.
    • A prostacyclin production defect, responsive to normal plasma, is a potential underlying cause.
    • Case reports indicate plasma infusion or exchange may be more effective than hemostatic inhibitors.

    Conclusions:

    • Uncontrolled platelet-endothelial interaction is a likely cause of HUS microthrombi.
    • Prostacyclin deficiency correctable by plasma is a probable pathogenic mechanism.
    • Further research should confirm the effectiveness of plasma therapy for HUS remission.

    Related Experiment Videos